Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Eur Heart J Acute Cardiovasc Care ; 9(2): 149-157, 2020 Mar.
Article in English | MEDLINE | ID: mdl-30456984

ABSTRACT

BACKGROUND: The use of percutaneous left ventricular assist devices in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) is evolving. The aim of the study was to assess the long-term outcome of patients with AMICS depending on early initiation of Impella CP® support prior to a percutaneous coronary intervention (PCI). METHODS: We retrospectively reviewed all patients who underwent PCI and Impella CP® support between 2014 and 2016 for AMICS at our institution. We compared survival to discharge between those with support initiation before (pre-PCI) and after (post-PCI) PCI. RESULTS: A total of 73 consecutive patients (69±12 years old, 27.4% female) were supported with Impella CP® and underwent PCI for AMICS (34 pre-PCI vs. 39 post-PCI). All patients were admitted with cardiogenic shock, and 58.9% sustained cardiac arrest. Survival at discharge was 35.6%. Compared with the post-PCI group, patients in the pre-PCI group had more lesions treated (p=0.03), a higher device weaning rate (p=0.005) and higher survival to discharge as well as to 30 and 90 days after device implantation, respectively (50.0% vs. 23.1%, 48.5% vs. 23.1%, 46.9 vs. 20.5%, p < 0.05). Kaplan-Meier analysis showed a higher survival at one year (31.3% vs. 17.6%, log-rank p-value=0.03) in the pre-PCI group. Impella support initiation before PCI was an independent predictor of survival up to 180 days after device implantation. CONCLUSIONS: In this small, single-centre, non-randomized study Impella CP® initiation prior to PCI was associated with higher survival rates at discharge and up to one year in AMICS patients presenting with high risk for in-hospital mortality.


Subject(s)
Heart-Assist Devices/adverse effects , Myocardial Infarction/complications , Percutaneous Coronary Intervention/methods , Shock, Cardiogenic/etiology , Acute Disease , Aged , Aged, 80 and over , Case-Control Studies , Combined Modality Therapy , Female , Hospital Mortality/trends , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/surgery , Non-Randomized Controlled Trials as Topic , Patient Discharge/trends , Retrospective Studies , Survival Rate , Treatment Outcome
2.
Thromb Haemost ; 115(5): 993-1000, 2016 05 02.
Article in English | MEDLINE | ID: mdl-26763077

ABSTRACT

A growing body of evidence suggests a pivotal role of inflammatory processes in AF in a bidirectional manner. Infiltrating leukocytes seem to promote both structural and electrical remodelling processes in patients with AF. Monocyte-platelets-aggregates (MPAs) are sensitive markers of both platelets and monocyte activation. So far it is not clear whether the content of MPAs is affected by AF. The present study examined the content of MPAs and the activation of monocytes in elderly patients with an aortic stenosis in dependence of AF. These patients are known to have a high prevalence of AF. Flow-cytometric quantification analysis demonstrated that patients with AF have an increased content of MPAs (207 ± 13 cells/µl vs 307 ± 21 cells/µl, p< 0.001), and enhanced expression of CD11b on monocytes (p< 0.001), compared to patients in stable sinus rhythm (SR). The number of CD14+/CD16+ monocytes were only slightly elevated in patients with AF. These findings were seen in patients with permanent AF. But also patients with paroxysmal AF, even when presenting in SR, the MPAs were increased by 50 % (p< 0.05) as well as the CD11b expression, which was twice as high (p< 0.05) compared to stable SR. These results demonstrate for the first time a dependency of MPAs and CD11b expression on monocytes in the presence of AF and support the notion of a close relationship between AF, thrombogenesis and inflammation. The content of MPAs and the extent of activation on monocytes appear promising as biomarkers for paroxysmal AF and as possible future targets for developing novel pharmacological therapeutic strategies.


Subject(s)
Aortic Valve Stenosis/blood , Aortic Valve Stenosis/complications , Atrial Fibrillation/blood , Atrial Fibrillation/complications , CD11b Antigen/blood , Aged, 80 and over , Aortic Valve Stenosis/immunology , Atrial Fibrillation/immunology , Biomarkers/blood , Blood Platelets/pathology , Cell Aggregation , Female , Humans , Inflammation Mediators/blood , Male , Monocytes/immunology , Monocytes/pathology , Platelet Activation , Platelet Aggregation , Thrombosis/blood , Thrombosis/etiology , Thrombosis/immunology
3.
Scand Cardiovasc J ; 49(6): 361-6, 2015.
Article in English | MEDLINE | ID: mdl-26287645

ABSTRACT

OBJECTIVE: The soluble form of ST2 (sST2) is a novel laboratory parameter for cardiac risk prediction, and over the past years, several studies have tried to evaluate its utility, especially in the management of heart failure. We investigated whether increased serum levels of sST2 show a characteristic pathomorphologic pattern in 3-Tesla cardiac magnetic resonance imaging (CMRI). METHODS: One hundred and fifty-six patients referred to 3T CMRI due to suspected coronary artery disease (CAD) or myocarditis were prospectively enrolled in the study. Ninety patients were diagnosed with CAD, 22 patients with myocarditis, and 44 patients, who constituted the reference group, showed no pathologic CMRI pattern. RESULTS: There was no significant difference between the sST2 values for patients in the reference group and patients with CAD or myocarditis. The sST2 concentration showed a weak correlation with the NYHA functional class (P = 0.002, r = 0.22), but correlation of sST2 and LGE, left ventricular parameters, and LVEF could not be seen. In contrast NT-proBNP was positively correlated to left ventricular parameters, LGE, and NYHA class function (P < 0.05). Additionally, it showed an inverse relationship to LVEF (P < 0.001, r = - 0.42). CONCLUSIONS: Soluble ST2 is not able to detect myocardial scar and should not be used alone as a parameter for detection of inflammation and myocardial scar formation.


Subject(s)
Coronary Artery Disease/blood , Coronary Artery Disease/pathology , Magnetic Resonance Imaging , Myocarditis/blood , Myocarditis/pathology , Myocardium/metabolism , Myocardium/pathology , Receptors, Cell Surface/blood , Adult , Aged , Biomarkers/blood , Case-Control Studies , Cicatrix/blood , Cicatrix/pathology , Coronary Artery Disease/physiopathology , Female , Fibrosis , Humans , Interleukin-1 Receptor-Like 1 Protein , Male , Middle Aged , Myocarditis/physiopathology , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Predictive Value of Tests , Prospective Studies , Stroke Volume , Up-Regulation , Ventricular Function, Left
4.
Muscle Nerve ; 52(4): 661-3, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26032656

ABSTRACT

INTRODUCTION: Cardiac dysfunction occurs in several forms of limb girdle muscular dystrophy (LGMD). The aim of this study was to investigate cardiac involvement in calpainopathy (LGMD2A). METHODS: Cardiovascular evaluation was performed in 10 patients with genetically verified LGMD2A by echocardiography, 3 Tesla - cardiovascular magnetic resonance, 24-h electrocardiography recordings with heart rate variability (HRV) analysis, and 24-h blood pressure recordings. RESULTS: No patient with calpainopathy showed impairment of left or right ventricular function. One patient had a small amount (2% of left ventricle mass) of late gadolinium enhancement. HRV analysis revealed no significant difference compared with external reference data. CONCLUSIONS: The main finding of this study is the lack of cardiac involvement in patients with calpainopathy. Cardiac involvement was not found, even in individuals with advanced age and greater disease severity. Furthermore, we did not observe an overall reduction of cardiac autonomic regulation in calpainopathy.


Subject(s)
Cardiovascular System/physiopathology , Heart/physiopathology , Muscular Dystrophies, Limb-Girdle/pathology , Muscular Dystrophies, Limb-Girdle/physiopathology , Adult , Blood Pressure , Echocardiography , Female , Heart Rate/physiology , Humans , Imaging, Three-Dimensional , Magnetic Resonance Spectroscopy , Male , Middle Aged , Young Adult
5.
Clin Auton Res ; 25(3): 189-91, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25822581

ABSTRACT

We present a case of a 57-year-old female patient with transient global amnesia, who later developed broken heart syndrome also known as takotsubo cardiomyopathy. The present case underlines that co-occurrence of both pathologies might still be an under-recognized clinical problem.


Subject(s)
Amnesia, Transient Global/pathology , Takotsubo Cardiomyopathy/pathology , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/physiopathology , Amnesia, Transient Global/complications , Echocardiography , Electrocardiography , Female , Humans , Middle Aged , Neurologic Examination , Neuropsychological Tests , Takotsubo Cardiomyopathy/complications , Treatment Outcome
7.
Scand Cardiovasc J ; 48(3): 176-83, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24650089

ABSTRACT

OBJECTIVES: For evaluation of aortic valve area (AVA), transthoracic echocardiography (TTE) is the method of choice. Cardiac magnetic resonance (CMR) at 1.5-Tesla is an alternative. The aim of the study was to check whether quantification of whole range of AVA without severe aortic stenosis is possible and reliable in higher magnetic field strength, and also including a comparison to TTE. METHODS: In 3-T CMR phase contrast sequences were assessed above aortic valve and left ventricular output tract. AVA was calculated using the continuity equation. Planimetric analysis of AVA was performed in magnitude images. TTE was used as reference method for graduation of AVA. RESULTS: Totally 48 patients (64 ± 18 years) without severe aortic valve stenosis were prospectively enrolled. In CMR planimetric AVA was 2.5 ± 1.3 cm(2) and calculated AVA 2.4 ± 1.3 cm(2), whereas AVA in TTE was 1.9 ± 1.1 cm(2). Planimetric and calculated AVA in CMR and also AVA in CMR and TTE showed good correlation (r = 0.97, 0.92, respectively). Bland-Altman analysis demonstrated no signs of over- or underestimation. Inter- and intraobserver variabilities were low. DISCUSSION: Determination of AVA using 3-T CMR is possible using direct planimetry and continuity equation. CMR is the alternative first choice method in cases with discrepant or insufficient echocardiographic results.


Subject(s)
Aortic Valve Stenosis/diagnosis , Aortic Valve/diagnostic imaging , Echocardiography , Magnetic Resonance Imaging , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...